"Today's cancer research brings tomorrow's cures!©"
PMP Cure Research
Appendix Cancer Research
Colorectal Cancer Research
Donate to Research
Gastric Cancer Research
Inflammatory Bowel Disease Research
Mesothelioma Research
Peritoneal Carcinomatosis Research
Peritoneal Surface Malignancy Research
Pseudomyxoma Peritonei Research
Research Funding Sources
Here are listings of
research studies and clinical trials taking place around the world for the treatment of
Colorectal
Cancers, Gastric Cancers, Mesothelioma,
Ovarian Cancer,
Pancreatic Cancer,
Pseudomyxoma Peritonei, Peritoneal Carcinomatosis, Mucinous Adenocarincoma and Appendix cancer, in general.
New research studies and clinical trials for the treatment of Colorectal Cancers, Gastric Cancer, Mesothelioma, Ovarian Cancer, Panceatic Cancer, Pseudomyxoma Peritonei, Appendix Cancer and Peritoneal Carcinomatosis are posted here as they become available.
See also: our SURGEONS & SPECIALISTS page for additional direct contact information regarding new research to cure PMP and the financial support of those studies.
Additional studies and clinical trials for the treatment of Pseudomyxoma Peritonei, Peritoneal Carcinomatosis and Appendix Cancers are listed on our CHEMOTHERAPY page as well as our TREATMENTS page.
Support Appendix Cancer and PMP Cure Research
This page includes information about how donors can financially support and contribute to Appendix Cancer and PMP Cure research being conducted by the individual specialists. Each researcher's address is and contact information is provided, enabling donors to send contributions directly to donate to research while bypassing the administrative "middle men."
Cancer Cure Research Grant Opportunities
Texas Invests $61 Million for Cancer Research
Source: Associated Press January 2010
Foundation for Digestive Health and Nutrition: $3 Million for Research Grants
Source: Foundation for Digestive Health 2010
Foundation for Digestive Health Funds Gastric Cancer Risk/Helicobacter Pylori Research
Source: Foundation for Digestive Health, 2009
Texas Invests $3 Billion for Cancer Research
Source: Associated Press and ABC News October 2009
NIH Research Grants
NIH Office of Rare Disorders
Source: NIH
American Association of Cancer Research Funding Opportunities
Source: AACR
AACR Annual Meeting 2010 Dedicated to Research
Source: AACR
ASCO Research Grants
NORD Research Grant Programs
Source: NORD
NCCN Oncology Research Grant Program
Source: NCCN
Comparative Effectiveness Research Plan in the US
AUSTRALIA
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH and MESOTHELIOMA
Research Studies at the UNSW under the direction of Prof. David L Morris* include:
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Pseudomyxoma Peritonei: investigation of a variety of compounds which appear to be able to dissolve mucin and which may fundamentally alter the management of this condition. These are laboratory and animal studies at present.
Mesothelioma: laboratory and animal research programs are in progress to determine the cause(s) of short and long term outcomes between male and female patients.
International Peritoneal Mesothelioma data base, contact: Dr Tristan Yan
Financial contributions can be donated to the: Peritonectomy Foundation which is part of our University Foundation and is tax deductible in Australia.
For more information, contact:
Professor David L Morris
UNSW Department of Surgery
St George Hospital
Kogarah NSW 2217
Australia
Ph 61 2 9113 2070
Fax 61 2 9113 3997
Email david.morris@unsw.edu.au
Professor Pompiliu Piso, in Regensburg, Germany provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information and to contribute to Prof Piso's research, contact:
Prof. Dr. Pompiliu Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der Universität Regensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.:0941-944-6809
Fax:0941-944-6860
NORWAY
PSEUDOMYXOMA PERITONEI, PMCA 1, MOUSE MODELS
Histopathologic Study of PMCA 1 using mouse models
Source: BMC Cancer, 2007
UNITED KINGDOM
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
Source: Christies Hospital, Manchester UK, Aug 2008
UNITED STATES of AMERICA
Dr David L Bartlett, UPMC
PSEUDOMYXOMA PERITONEI PMP CURE, PERITONEAL CARCINOMATOSIS, APPENDIX CANCER, COLON CANCER, OVARIAN CANCER
Read a description of research conducted by Dr. David L Bartlett at UPMC
Development of tumor selective viral vectors/development of surgical procedures for regional treatment of malignant neoplasms
Source: Dr David L Bartlett
Development, research and study of efficiency for tumor regression using live mice
Donations for Dr Bartlett's research can be sent via:
via postal mail University of Pittsburgh Cancer Institute Development,
UPMC Cancer Pavilion – Suite 1B
5150 Centre Avenue, Pittsburgh, PA 15232
website for donations
or via postal mail David C. Koch Regional Cancer Therapy
200 Lothrop Street, Suite 8084
Pgh PA 15213
via telephone/credit card (412)623-4700 or
Article of Interest by Dr David L Bartlett:
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr. Jesus Esquivel, St. Agnes Hospital
PERITONEAL SURFACE MALIGNANCIES, HIPEC, PSEUDOMYXOMA PERITONEI RESEARCH
Laparoscopic CRS and HIPEC for Patients with limited Peritoneal Surface Malignancies
RPN: 2008-20
Protocol Status: Open
Evaluation of Novel Mucinolutic Agents for Pseudomyxoma Peritonei (Dissolving "PMP")
RPN: 2007-12
Protocol Status: Open
website for donations to Dr Esquivel's research
Contact Dr Eaquivel:
Jesus Esquivel, MD, FACS
Director, Peritoneal Surface Malignancy Program
St. Agnes Hospital
900 Caton Ave
Mail Box 207
Baltimore, Maryland 21229
USA
Phone: 410-368-2743
Fax: 410-951-4007
email: jesquive@stagnes.org
web: www.hipec.org
Source: Dr Jesus Esquivel provided this information to the PMP Pals' Network, 2010
Dr. Laura A. Lambert
UMass Memorial Medical Center
PERITONEAL SURFACE MALIGNANCY, PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, APPENDICEAL CANCER, HIPEC
Dr Laura L Lambert is conducting the following research via the UMass Memorial Medical Center
Peritoneal Surface Malignancy Research Program:
1. Alternative solutions in hyperthermic intraperitoneal perfusion
Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IC) are considered the standard of care for patients with peritoneal dissemination of appendiceal cancer, ovarian cancer and peritoneal mesothelioma. Data are also accumulating that show a survival advantage for this approach in selected patients with carcinomatosis for colorectal cancer. However, there is no consensus as to the optimal form of IC. Usage of a wide variety of chemotherapy agents, in various carrier solutions, administered either with or without hyperthermia, for a broad range of times (30 minutes to days), has been reported with remarkably comparable rates of success. Consequently, the optimal form of IC is unknown, while on the other hand, clinically significant systemic side effects are well-documented. The main goal of this project is to investigate alternative peritoneal perfusion techniques that result in tumor –specific cell death with less systemic toxicity. Identification of tumor-specific cytotoxic peritoneal perfusates will improve oncologic outcomes combined with decreased toxicity for patients undergoing CRS and HIPEC.
2. DNA and Protein microarray investigation of appendiceal cancer
Because non-carcinoid appendical cancers are extremely rare, little is known about the genetic pathways that are involved in the growth and dissemination of these tumors. The purpose of this research project is to investigate the genetic and protein expression profiles of non-carcinoid appendiceal cancers. The potential benefits of this project are to identify novel targets for therapy, provide better prognostic information, and identify people at risk for developing appendiceal cancer based upon genetic and protein profiles.
3. Cell cycle-targeted therapy enhances tumor cell death during HIPEC
The ultimate goal of all cancer therapy is cancer-specific cell death, without harming normal cells. Because all cancer cells lose regulation of their cell cycle, cancer therapies that target the cell cycle are appealing and rational. Recent studies from our laboratory targeted the cell cycle in normal, sarcoma and colon cancer cell lines with a cell cycle inhibitor after exposure to chemotherapy. In these studies, the combined treatment resulted in significantly enhanced cell death in the cancer cell lines, but not in the normal cells. Based upon these findings, the main hypothesis of this project is that increased cytotoxicity by cell cycle inhibition after chemotherapy specifically enhances cancer cell death while sparing normal cells. Our objective is to translate our preliminary findings of cell cycle-induced cancer cell death in to improved outcomes for patients undergoing HIPEC.
4. Cytokine and protein profiles of malignant ascites
Patients with peritoneal ascites often suffer debilitating symptoms including life-threatening anorexia and cachexia. Symptom management is challenging and often inadequate, resulting in loss of quality of life (QoL). This study is investigating the cytokine and other protein profiles of malignant and non-malignant ascites for potential targets for palliation. This is an on-going prospective, observational study at the UMass Memorial Medical Center. Patients with ascites retrieved either at surgery or by paracentesis are asked to complete a brief QoL questionnaire. Relative intensity of cytokine and protein expression in the ascites fluid is quantified. Significant differences between non-malignant and malignant ascites are determined and correlated with QoL data. Through this study we hope to identify targets for more effective palliation of symptomatic ascites. So far we have identified angiogenin as a potential target for anti-angiogenic therapy in malignant ascites. In addition, the appetite suppressant, leptin, may be a potential target for palliation of ascites-related anorexia.
5. The role of mucin-regulating hormones in pseudomyxoma peritonei (PMP)
Luteinizing hormone (LH) and beta human chorionogranin (b-HCG) have been shown to play a significant role in the production of gynecologic-associated mucins. The role of sex hormones in the production of gastrointestinal mucin, including that produced by the appendix, has never been determined. The purpose of this project is to investigate the role of sex hormones in the production of gastrointestinal mucin. The potential benefit of the results of this study is to identify a hormone-based therapy for the management of PMP.
Here is how you can donate to Dr Laura A Lambert's research:
UMass Memorial Peritoneal Surface Malignancy Research Program Fund
Donations for Dr Lambert's research can be sent via:
via postal mail:
UMass Medical School/UMass Memorial Development Office
333 South Street
Shrewsbury, MA 01545
via personal check:
Please make your check payable to UMMF.
IMPORTANT: You MUST write “Laura Lambert MD Research Fund” in the “memo/for” field on your check to direct your gift to the correct fund.
via online:
Click this link for online donations
Under #1 “Direct My Gift”, check the box for “OTHER”.
IMPORTANT: In the Comments section please type:" UMass Memorial Peritoneal Surface Malignancy Research Program Fund."
To learn more about Laura Lambert's, M.D. research, clink this link Laura A. Lambert, MD.
For questions regarding your gift please visit Ways of Giving or call 508-856-5520.
This research program is classified as a 501(c)(3).
Laura A. Lambert, MD
Adult Specialties Surgery - Oncology
Gastrointestinal cancer, management of peritoneal based malignancies such as appendiceal cancer and carcinomatosis
UMass Memorial Medical Center - Memorial Campus
119 Belmont Street
Worcester, MA 01605
Tel: 508-334-5274 Fax: 508-334-5089
Source: Dr Lambert provided this information to the PMP Pals' Network, 2010
Dr Edward A Levine, Wake Forest University
APPENDIX CANCER, COLORECTAL, HIPEC, PERITONEAL SURFACE DISEASES
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
Source: Wake Forest University
Source: Codex
Edward A. Levine, M.D., Professor of Surgery and Chief of Surgical Oncology at Wake Forest University in Winston-Salem, North Carolina , USA, and his colleagues, conduct three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface diseases. Additionally, this research team participates in a national registry for HIPEC cases.
These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research,
call Joyce Fenstermaker R.N. at 336 713 3155, EST
Dr Brian Loggie, Creighton University
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, DPAM, MESOTHELIOMA
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Dr Brian Loggie has created several programs for research in the treatment of PMP and Mesothelioma as follows:
The Creighton University School of Medicine Cancer Biology Program, Omaha, NE,USA
The Cancer Biology program at the Creighton University School of Medicine is directed by Dr. Brian Loggie, professor of surgery, and chief of the division of surgical oncology. He has created a translational working group (TWG) consisting of surgical oncologists, pathologists and basic scientists working collaboratively on several projects relating to Pseudomyxoma Peritonei cure research.
The TWG has begun research identifying mutations in multiple target genes. They are categorizing the mutations on the basis of known signaling pathways in order to combine this knowledge with known pathologic variables and patient outcome. With new biologic insights, it will be possible to consider new approaches to clinical strategies and laboratory testing for PMP patients. The TWG has worked successfully together.
The TWG has previously been successful in identifying novel mutations in the epidermal growth factor (EGFR) gene in Mesothelioma, identifying the biologic implications, confirming the mutation effects on cell signaling function in the laboratory, and devising new treatment strategies.
The TWG seeks to develop information which correlates with prognosis, which aids in developing new treatments, and may guide treatment selection for various presentations and forms of PMP.
The TWG is also continuing to focus on the biology of mucin (specific types of which are generated by PMP tumors), particularly when it is blocked or down-regulated. Our research is showing that if we block mucin production, we can influence PMP tumor cell growth, and even arrest development of these cells. The development of this knowledge will expand treatments for Pseudomyxoma Peritonei patients.
Related website: http://medschool.creighton.edu/medicine/centers/cancer/res/studies/index.php
Contact person to be notified for patient participation in the program:
Holly Sennett, A.P.R.N.-B.C.
Phone: 402-280-5200
To donate to Dr Brian W Loggie's research, make checks payable to “Creighton University” with “PMP Patients Fund” in the ‘memo’ section of the check. 100% of the proceeds will be directed to PMP research.
Inquiries regarding donations may be directed to:
Matt Gerard
Senior Director of Philanthropy
Creighton University
2500 California Plaza
Omaha, NE 68178
P: 402.280.5746 or 800.334.8794
Brian W. Loggie, MD, CM, FRCSC, FACS
Harold J. Bonnstetter Professor of Surgery
Chief, Division of Surgical Oncology
Creighton University Medical Center
601 N. 30th St, Omaha, NE 68131
Ph: (402) 280-5009 Fax: (402) 280-3448
The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a non-profit 501 (c)(3) organization that promotes research, education and patient care in gastrointestinal oncology. FARGO's primary objective is to facilitate the transfer of basic science research into innovations in patient care. The responsibilities of FARGO include financial support, administrative support, and space for continued progress in the prevention and treatment of gastrointestinal cancer.
Donations to FARGO are tax deductible and can be made to:
FARGO
c/o Washington Hospital Center
106 Irving St., NW
Suite 3900
Washington, D.C. 20010
Dr Herbert J Zeh III, University of Pittsburgh
PSEUDOMYXOMA PERITONEI
Identification of molecular targets in Pseudomyxoma Peritonei via clonal analyses of metastases.
Herbert J. Zeh, III, MD
Assistant Professor of Surgery
Division of Surgical Oncology
University of Pittsburgh
Pittsburgh, PA, USA
Profile for Dr Herbert J Zeh
INTERNATIONAL
ASCO reviews NEW clinical trials for GI and Colon cancersSource: ASCO 2009
International Cancer Genome Consortium
UNC Center for Functional GI and Motility Disorders
Research studies for GI and Motility Disorders
Source: UNC 2009
Vanderbilt Clinic
COLORECTAL CANCERS
Clinical Trials for Colorectal Cancers at Vanderbilt ClinicAdditional Services and Studies
Merck Clinical Study MK2206 recruiting patients w/locally advanced or metastatic solid tumors
Source: Merck, 2009
CenterWatch Clinical Trials Listing Service
Free subscription
Research Gate Data BaseFree subscription
United States Military Cancer Institute
Gene Therapy
Leukocyte Therapy for Patients with Unresectable Cancer
http://clinicaltrials.gov/ct2/show/NCT00607802?term=cui&rank=5White Blood Cell Transfer for Patients with Unresectable Cancer
http://www.cancer.gov/clinicaltrials/CCCWFU-99107
Granulocyte Research
http://munogenics.comAspirin Use for Chemoprotection of Colorectal Adenoma CancersSource: Journal of the National Cancer Institute, June 2009
Results of Phase III Systemic Chemotherapy Trial for Advanced Gastric Cancer
Source: Annals of Oncology, July 2009
Pseudomyxoma Peritonei
Click here to read more about Pseudomyxoma PeritoneiThis page has been contributed by the family, friends and colleagues of Marcus "Dwain" Reynolds.
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright © 2010 by the PMP Pals' Network
